Neurological disorders

Jiffy Lube® and Muscular Dystrophy Association Celebrate 10th Annual Fundraising Campaign to Support the Neuromuscular Community

Retrieved on: 
Tuesday, July 27, 2021

During the month of August, Jiffy Lube customers will be invited to make a donation of$3or more to MDA at participating Jiffy Lube centers.

Key Points: 
  • During the month of August, Jiffy Lube customers will be invited to make a donation of$3or more to MDA at participating Jiffy Lube centers.
  • "I'm honored to support the Muscular Dystrophy Association and Jiffy Lube's efforts to fund breakthrough science and care and commend them for their decade-long dedication of driving to do more to support MDA's mission."
  • "I'm so happy to be part of the Jiffy Lube campaign, because it is raising awareness about muscular dystrophy that I live with," said Maddee Helaire, MDA Ambassador.
  • For decades, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

Retrieved on: 
Tuesday, July 27, 2021

11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.

Key Points: 
  • 11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.
  • One or more electrodes apply electrical impulses through the patient's skin modulating a targeted nerve to treat the medical condition.
  • This newly allowed patent is owned by electroCore and is the latest U.S. patent to issue in connection with the companys non-invasive development program for pain.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Retrieved on: 
Monday, July 26, 2021

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.

Key Points: 
  • These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.
  • The OVERTURE study demonstrated that gamma frequency neuro-modulation led to a significant reduction in brain atrophy in AD patients.
  • Accelerated brain atrophy is associated with cognitive decline and loss of function in AD patients and is a driver of mortality and morbidity in Alzheimers disease progression.
  • Cognito Therapeutics is a clinical-stage neuro-physiology company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimers disease.

Race Is Among the Factors That Predicted How Quickly Stroke Patients Get to Stroke Centers to Receive Essential Surgery, Study Shows

Retrieved on: 
Monday, July 26, 2021

The faster patients who need this surgery receive it, the better their chances are of avoiding death or long-term disability from stroke.

Key Points: 
  • The faster patients who need this surgery receive it, the better their chances are of avoiding death or long-term disability from stroke.
  • The researchers found that race was among the predictors for how quickly patients made it to a stroke center, which impacts how quickly they can have surgery.
  • Other factors included driving distance, the patient's stroke severity level and whether a patient discovered the stroke symptoms upon waking.
  • "This study shows that equity of access to care is critically important in achieving excellent outcomes for all."

ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Thursday, July 22, 2021

TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.
  • ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.
  • Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.
  • Both presentations will be available on the ProMIS website ( www.promisneurosciences.com ) after the AAIC closes on July 30.

Zogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5

Retrieved on: 
Thursday, July 22, 2021

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
  • Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Zogenix Product FINTEPLA® (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment Outcomes

Retrieved on: 
Wednesday, July 21, 2021

Authors also recognize FINTEPLA for achieving clinically important results in caregiver-reported outcomes such as patient and family quality of life.

Key Points: 
  • Authors also recognize FINTEPLA for achieving clinically important results in caregiver-reported outcomes such as patient and family quality of life.
  • In their assessment, the authors write that future Dravet syndrome treatments should be evaluated against the demonstrated efficacy of fenfluramine.
  • FINTEPLA was approved in the U.S. and European Union in 2020 for the treatment of seizures associated with Dravet syndrome patients aged two years and older.
  • The authors write that the novel outcomes reported with FINTEPLA treatment, such as effects on executive functions, have effectively raised the bar for assessment of future therapies.

Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease

Retrieved on: 
Thursday, July 15, 2021

Dr Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen, said We are excited to enter this licensing agreement with IRLAB.

Key Points: 
  • Dr Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen, said We are excited to enter this licensing agreement with IRLAB.
  • By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinsons disease experiencing levodopa-induced dyskinesia.
  • Dr Nicholas Waters, CEO of IRLAB, said We believe in the potential of investigational mesdopetam for people with Parkinsons disease experiencing dyskinesia or psychosis.
  • The agreement and partnership with Ipsen is a validation of our proprietary discovery platform, ISP, and our drug development efforts.

California Passes $15 Million in Funding for the Treatment and Care of People Living with ALS

Retrieved on: 
Thursday, July 15, 2021

The initial funding grant, $9 million over the course of the last three years, expired in June.

Key Points: 
  • The initial funding grant, $9 million over the course of the last three years, expired in June.
  • The new allocation ensures that patients and families living with ALS across the state of California receive the specialized medical care needed to extend and improve quality of life.
  • The ALS Association is the largest philanthropic funder of ALS research in the world.
  • The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure.

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

Retrieved on: 
Friday, July 9, 2021

Muna is focused on addressing the staggering unmet need experienced by patients around the world with neurodegenerative disorders.

Key Points: 
  • Muna is focused on addressing the staggering unmet need experienced by patients around the world with neurodegenerative disorders.
  • Muna has built a cutting-edge small molecule drug discovery engine that leverages high-resolution target structural approaches, AI-driven computational chemistry and cell-based screening.
  • "Our team is committed to leveraging our collective expertise to deliver impactful disease modifying small molecule therapeutics to patients as rapidly as possible."
  • Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia and Parkinson's.